The interactions between patient advocacy organizations and biopharmaceutical companies are critical, although often complex, and collaborations between these two stakeholders have increased in recent years as patient advocacy organizations have evolved and become increasingly engaged.
Given the complexity of drug development, many patient advocacy organizations desire clarity and guidance on effective approaches to engaging with the biopharmaceutical industry to realize their vision of meaningful therapeutics. Our team created the resource below to outline that all interactions between Solve M.E., industry, and the disease community should be transparent; should enable trust, accountability, and shared learning; and ultimately should work most efficiently and effectively toward advancing meaningful health outcomes for patients.
Read Solve’s Guidelines on Interactions with Biopharmaceutical Companies here.
